Original Article
Natural History of Peripheral Neuropathy in Patients with Non-Insulin-Dependent Diabetes Mellitus
N Engl J Med 1995; 333:89-94July 13, 1995
- Abstract
Background
There is little information on the incidence and natural history of neuropathy in patients with non-insulin-dependent diabetes mellitus (NIDDM).
Methods
We studied patients with newly diagnosed NIDDM and control subjects both at base line and 5 and 10 years later. Polyneuropathy was diagnosed on the basis of clinical criteria (pain and paresthesias) and electrodiagnostic studies (nerve conduction velocity and response-amplitude values). We investigated the relation between metabolic variables (results of oral glucose-tolerance tests, serum lipid and insulin concentrations, and glycosylated hemoglobin values) and the development of polyneuropathy.
Results
In 10 years, 36 patients with NIDDM and 8 control subjects died; 86 patients and 121 control subjects completed the study. When the study ended, 18 percent of the patients were being treated only with diet, 59 percent with oral hypoglycemic drugs alone, 12 percent with insulin alone, and 11 percent with both insulin and oral hypoglycemic agents. At base line the prevalence of definite or probable polyneuropathy among the patients with NIDDM was 8.3 percent, as compared with 2.1 percent among the control subjects. These values 10 years later were 41.9 percent and 5.8 percent, respectively. The number of patients with NIDDM who had nerve-conduction abnormalities in the legs and feet increased from 8.3 percent at base line to 16.7 percent after 5 years and to 41.9 percent after 10 years. The decrease in sensory and motor amplitudes, indicating axonal destruction, was more pronounced than the slowing of the nerve conduction velocities, which indicates demyelination. Among the patients with NIDDM, those with polyneuropathy had poorer glycemic control than those without. Low serum insulin concentrations before and after the oral administration of glucose were associated with the development of polyneuropathy, regardless of the degree of glycemia.
Conclusions
The prevalence of polyneuropathy among patients with NIDDM increases with time, and the increase may be greater in patients with hypoinsulinemia.
Media in This Article
Figure 2
Patients with NIDDM and Control Subjects with Definite or Probable Polyneuropathy at Base Line and after 10 Years.Figure 3
Prevalence of Polyneuropathy after 10 Years of Follow-up in Patients with NIDDM, According to the Mean Fasting Plasma Glucose Concentration and the Base-Line Fasting Serum Insulin Concentration.Article Activity
- Article
There is little information available on the incidence and natural history of neuropathy diagnosed according to clinical and electrodiagnostic criteria in patients with non-insulin-dependent diabetes mellitus (NIDDM). Up to 7.5 percent of patients with NIDDM have clinical neuropathy at the time of diagnosis. This rate increases to 50 percent among patients who have had diabetes for 25 years.1 In an earlier study of patients with NIDDM, we found that 15.2 percent had abnormalities in nerve conduction velocity at the time of diagnosis, but only 2.3 percent had clinical signs of polyneuropathy and 1.5 percent had symptomatic polyneuropathy.2 After five years of follow-up, changes in neurophysiologic measurements in this group were slight and were associated with poor glycemic control.3 In this report we describe the results of studies of peripheral-nerve function after 10 years of follow-up in this cohort of patients with NIDDM and in control subjects; our goal was to determine the long-term risk of diabetic polyneuropathy and the factors affecting that risk.
Methods
We recruited 133 patients with newly diagnosed NIDDM who were 45 to 64 years old at the time of diagnosis and 144 randomly selected nondiabetic control subjects in the same age group (Table 1Table 1
Characteristics of the Patients with NIDDM and the Control Subjects at Base Line.).2 Both groups were evaluated between May 1, 1979, and December 31, 1981.4 The control subjects were recruited from among 180,000 inhabitants of the county of Kuopio in eastern Finland. At base line, 132 patients with NIDDM and 142 control subjects underwent clinical evaluation and measurement of nerve conduction velocity. Of these, 114 patients with NIDDM (86 percent) and 128 control subjects (90 percent) were evaluated after 5 years of follow-up, and 86 (65 percent) and 121 (85 percent), respectively, after 10 years. The diagnosis of diabetes4 was confirmed by an oral glucose-tolerance test, in which subjects were given 75 g of glucose after a 12-hour overnight fast5; the test was performed in both the diabetic patients and the control subjects. Information about cigarette smoking and the use of alcohol was obtained by questionnaire. During the 10-year follow-up period, 36 patients with NIDDM and 8 control subjects died; the cause of death in the patients with NIDDM was most often cardiovascular.6 The study was approved by the ethics committee of the University of Kuopio, and all the subjects gave informed consent.The patients were initially treated only with diet. Thereafter, antidiabetic therapy, as well as other therapy, was managed by the patients' primary care physicians. At the five-year examination, 50 percent of the patients were being treated with oral hypoglycemic drugs, 4 percent with insulin, and the rest with diet only. At the 10-year examination, 59 percent were receiving only oral hypoglycemic drugs, 12 percent were taking insulin, 18 percent were treated with diet alone, and 11 percent were treated with both oral hypoglycemic drugs and insulin. The metabolic follow-up data are shown in Table 2Table 2
Metabolic Data for the Patients with NIDDM and the Control Subjects at the 5-Year and 10-Year Examinations..Laboratory Studies
Glucose tolerance was assessed by measuring blood or plasma glucose concentrations (in blood at base line and in plasma at 5 and 10 years) and serum insulin and C-peptide concentrations before and one and two hours after the oral administration of 75 g of glucose. Glucose was measured by the glucose oxidase method (at base line and at the 10-year examination) or the glucose dehydrogenase method (at 5 years).7 Serum insulin was measured by a double-antibody radioimmunoassay (at base line: Novo Industries, Copenhagen, Denmark; at 5 and 10 years: Phasedeph, Pharmacia, Uppsala, Sweden). Serum C peptide was measured by radioimmunoassay (at 5 years: Novo-Nordisk, Copenhagen; at 10 years: 125-I, Incstar, Stillwater, Minn.).7
At all examinations, serum lipid concentrations were determined in samples obtained after the subjects had fasted for 12 hours. Lipoproteins were analyzed enzymatically after ultracentrifugation and precipitation.6,8 Glycosylated hemoglobin was measured at the 5-year and 10-year examinations by liquid cation-exchange chromatography (normal range, 4.0 to 6.0 percent). In the base-line study, albumin was measured by immunodiffusion in 24-hour urine samples (Behringswerke, Mahrburg Lahn, Germany).
Neurologic Examination
A detailed neurologic examination, including a questionnaire on symptoms, was performed at base line and at the 10-year follow-up examination. At the five-year follow-up examination, only electrophysiologic studies were performed.3 Neuropathic pain was defined as pain in the limbs in the absence of a history of trauma or other evident external cause. Pain that arose during exercise and disappeared at rest, joint pain, and back pain radiating to the legs were not considered neuropathic pain. Bilateral pain or paresthesias of the legs or feet were considered symptoms of polyneuropathy. The limbs were inspected for ulcerations and muscle atrophy. The patellar and Achilles-tendon reflexes were examined. Vibration sensation was tested with a tuning fork (128 Hz) on each medial malleolus. The absence of either Achilles-tendon reflexes or vibration sensation bilaterally was considered a clinical sign of polyneuropathy. All the subjects were also evaluated for carpal tunnel syndrome at base line.
Neurophysiologic Studies
Measurements of nerve conduction velocity at base line and at the 5-year and 10-year examinations were performed with a DISA 1500 electromyograph (Dantec, Skovlunde, Denmark). Conduction velocity in the median and deep peroneal motor nerves and antidromic conduction velocity in the superficial radial, median, sural, and superficial peroneal sensory nerves were measured by conventional methods with surface electrodes.9 The measurements in the motor nerves were performed principally on the left side of the body, but the right side was used if a local nerve lesion was suspected or if a response could not be elicited on the left side. The measurements in sensory nerves were performed bilaterally, and the mean of the values for the two sides (or the value for a unilateral measurement, if a response on the other side could not be elicited) was calculated. The amplitudes of the motor and sensory responses were measured to the first negative peak. All studies of nerve conduction velocity were done at room temperature (between 22 °C and 24 °C). Skin temperatures were measured with an ELLAB TE 3 thermometer (Elektrolaboratoriet, Copenhagen) at the sites of sensory-nerve measurements.9 Both directly measured values for nerve conduction velocity in the sensory nerves and values adjusted for the effect of temperature were analyzed.10
Definition of Diabetic Polyneuropathy
Because there was no significant decrease in the mean nerve conduction velocities in the control group during the 10-year follow-up period, we did not consider it necessary to correct these values for age,10 and the same cutoff points were used for normal measurements at all times (control mean, -2 SD). The normal values for the amplitudes of the motor- and sensory-nerve responses were more difficult to determine because of the large variation in values. We tabulated all values for amplitude in the control subjects at the 10-year examination and defined the lower limit of normal as the 10th percentile of the values for the legs and feet in the controls. Although the amplitudes diminished in all subjects during the 10-year follow-up, the cutoff value was so low in relation to the mean that adjustment for age was considered unnecessary. Altogether, six measurements of nerve function in the legs and feet were used as electrophysiologic indicators of polyneuropathy: in the peroneal motor nerves, nerve conduction velocity, less/equal 39 m per second; amplitude, less/equal 1 mV; in the peroneal sensory nerves, nerve conduction velocity, less/equal 37 m per second; amplitude, less/equal 2 microV; in the sural sensory nerves, nerve conduction velocity, less/equal 43 m per second; amplitude, less/equal 3 microV -- all at a skin temperature greater/equal 31 °C. The subjects were classified as having definite polyneuropathy if four or more values were abnormal, if both the peroneal and sural nerves were involved, and if there were clinical symptoms of polyneuropathy (pain or paresthesias in the legs); they were classified as having probable polyneuropathy if four or more values were abnormal and both the peroneal and sural nerves were involved but there were no symptoms, or if either of the nerves was electrophysiologically involved and there were symptoms. The subjects with definite or probable polyneuropathy were grouped together as subjects with polyneuropathy. Twenty-four patients with NIDDM and 15 control subjects had carpal tunnel syndrome at base line (P = 0.07). The nerve conduction values in the arms and hands were therefore not used to define polyneuropathy.
Statistical Analysis
The differences in mean values between the groups were analyzed by Student's t-test (two-tailed), the Mann-Whitney U test, or analysis of covariance with control for confounding variables. The categorical variables were analyzed by the chi-square test, McNemar's test, or Fisher's exact test. Time-related changes within a group were analyzed by paired t-tests or the Wilcoxon matched-pairs signed-rank test. Differences in the areas under the serum insulin curve (at base line, 5 years, and 10 years, with insulin-treated patients omitted) between the patients with and without neuropathy were analyzed by repeated-measures analysis of variance (for time of investigation, group, and fasting glucose value at base line and at 5 and 10 years). Serum insulin concentrations were analyzed after logarithmic transformation. The area under the serum insulin curve was calculated by the trapezoidal rule. The Spearman correlation coefficient was calculated for the relation between nerve function and the metabolic variables (glycemic control and serum insulin values). All the data were analyzed with SPSS software (SPSS, Chicago).
Results
The proportions of subjects with neuropathic pain or without vibration perception in the NIDDM and control groups at base line were similar, but paresthesias and an absence of Achilles-tendon reflexes were more common in the group with NIDDM (Figure 1AFigure 1
Prevalence of Clinical Symptoms and Signs in Patients with NIDDM and Control Subjects at Base Line and after 10 Years., Figure 1B, Figure 1C, and Figure 1D). All values for nerve conduction velocity in sensory and motor nerves were slower, and the sensory amplitude of the radial nerve and the motor amplitude of the median nerve were lower in the group with NIDDM (Table 3Table 3
Results of Electrophysiologic Studies of Peripheral-Nerve Function in Patients with NIDDM and Control Subjects at Base Line and at the 10-Year Examination.).At the five-year examination the nerve conduction velocity in the sural sensory nerves and the sensory response amplitude of the superficial peroneal nerve had decreased in the NIDDM group.3 The sensory amplitude of the median nerve was lower in both the NIDDM group (P<0.001) and the control group (P = 0.005) than at base line.
At the 10-year examination, clinical symptoms and signs of neuropathy were more common among the patients with NIDDM than among the control subjects (Figure 1A, Figure 1B, Figure 1C, and Figure 1D). The frequency of pain and paresthesias had increased since the base-line evaluation among the patients with NIDDM, as had the frequency with which Achilles-tendon reflexes and vibration perception were absent. None of these variables changed in the control subjects. Of the patients with NIDDM, one had foot ulcerations at base line and two had such ulcerations at the 10-year examination. All values for nerve conduction velocity and response amplitudes were lower in the patients with NIDDM than in the control subjects at the 10-year examination (Table 3). The decrease in the sensory response amplitudes during follow-up was more marked in the group with NIDDM than in the control group. The temperature correction for nerve conduction velocities10 had no effect on the results. The patients with NIDDM who died during follow-up did not have more neurophysiologic abnormalities earlier than those who survived.
At base line, six of the patients with NIDDM (4.5 percent) had probable polyneuropathy and five (3.8 percent) had definite polyneuropathy. At the 10-year examination, these figures were 18 (20.9 percent) and 18 (20.9 percent), respectively (Figure 2Figure 2
Patients with NIDDM and Control Subjects with Definite or Probable Polyneuropathy at Base Line and after 10 Years.). At base line, 8.3 percent of the patients had electrophysiologic abnormalities; 16.7 percent had such abnormalities at 5 years, and 41.9 percent at 10 years.Risk Factors for Polyneuropathy
Age, smoking, and the use of alcohol did not predict the occurrence of polyneuropathy at 10 years in the patients with NIDDM. At the five-year examination, the patients with polyneuropathy had lower mean (±SD) blood-pressure levels when seated than those without polyneuropathy (135 ±15 vs. 147 ±20 mm Hg, P = 0.003, for systolic blood pressure; and 81 ±7 vs. 86 ±11 mm Hg for diastolic blood pressure, P = 0.013). There were no significant differences in base-line serum lipid values, urinary albumin excretion, or antihypertensive drug therapy between the patients who had polyneuropathy at the 10-year examination and those who did not.
The mean fasting blood or plasma glucose concentrations at base line, 5 years, and 10 years were higher in the patients in whom polyneuropathy developed during the 10-year follow-up period than in those in whom polyneuropathy did not develop (223 ±23 vs. 204 ±50 mg per deciliter [12.4 ±1.3 vs. 11.3 ±2.8 mmol per liter], P = 0.002). Accordingly, the mean values for glycosylated hemoglobin at the 5- and 10-year examinations tended to be higher in the group with polyneuropathy (9.6 ±1.8 percent vs. 8.9 ±1.8 percent, P = 0.09). At base line, both fasting serum insulin concentrations and concentrations after the administration of glucose were lower in the group in whom polyneuropathy subsequently developed. The serum insulin and C-peptide concentrations in these two groups of patients after the administration of glucose were also different at the 10-year examination (Table 4Table 4
Serum Insulin and C-Peptide Values in Patients with NIDDM in Whom Definite or Probable Polyneuropathy Had Developed by the 10-Year Examination and in Those without Polyneuropathy.). The areas under the serum insulin curve at all three examinations were lower for the patients in whom polyneuropathy developed, even after we adjusted for the simultaneous fasting blood or plasma glucose values (or glycosylated hemoglobin, measured at the 5-year and 10-year examinations) (P = 0.03). We explored the combined effects of poor glycemic control and low serum insulin concentrations in a variety of multivariate analyses. There was insufficient information to allow us to determine the separate contributions of glycemic control and serum insulin concentrations to the occurrence of polyneuropathy (Figure 3Figure 3Prevalence of Polyneuropathy after 10 Years of Follow-up in Patients with NIDDM, According to the Mean Fasting Plasma Glucose Concentration and the Base-Line Fasting Serum Insulin Concentration.). The decreases in response amplitudes and nerve conduction velocities during the follow-up period were consistently correlated significantly with both poor glycemic control and low serum insulin values (data not shown).Discussion
We examined the occurrence of clinical polyneuropathy and electrophysiologic changes in nerve function during 10 years of follow-up of patients with newly diagnosed NIDDM. The prevalence of polyneuropathy at the time of diagnosis (8.3 percent) was similar to that reported by Pirart,1 Ratzmann et al.,11 and Mincu.12 We found a markedly higher frequency of polyneuropathy at 5 and 10 years in the patients with NIDDM than in the control subjects, suggesting a cumulative effect of neuropathic factors with time.
There is now strong evidence that good glycemic control can prevent the appearance and worsening of polyneuropathy in patients with insulin-dependent diabetes mellitus.13 Our findings in patients with NIDDM suggest that glycemic control is also important in these patients, but direct proof can be obtained only from controlled intervention studies. Axonal damage in the patients with NIDDM, indicated by decreasing sensory-amplitude values during the 10-year follow-up period, was also related to glycemic control. Moreover, poor glycemic control was associated with increased mortality from cardiovascular diseases in this cohort,6 a fact that may lessen the value of hyperglycemia in predicting the development of neuropathy.
Early metabolic abnormalities in the nerves of diabetic patients are thought to be due to the direct exposure of nerve tissue or its vascular bed to high concentrations of glucose.14,15 Hyperglycemia may increase the activity of the polyol pathway, resulting in the accumulation of sorbitol and fructose and a decrease in Na+/K+-ATPase activity.16 There is also loss of myelinated fibers,17 and demyelination may occur.18 Our results suggest that axonal degeneration is the main cause of diabetic polyneuropathy, because reduction of the amplitudes of the sensory and motor responses, reflecting axonal damage, was a more prominent feature than slowing of nerve conduction velocities, an indicator of demyelination.
In addition to poor metabolic control, the patients with NIDDM in whom polyneuropathy developed had lower serum insulin values at base line and lower serum insulin values after the ingestion of glucose at the 10-year examination. Although patients with poor glycemic control also had lower serum insulin responses to glucose,19 low serum insulin values were a predictor of polyneuropathy. This novel finding is supported by experimental studies that demonstrate that insulin or C peptide may have direct effects on nerve-tissue metabolism or function.14,20
Our results indicate that it is possible to use clinical and electrodiagnostic criteria to diagnose polyneuropathy in patients with NIDDM. The finding that both low serum insulin concentrations and hyperglycemia were related to the risk of diabetic neuropathy suggests that early insulin therapy for patients with NIDDM who have diminished insulin secretion may have neuroprotective effects.
Supported by grants from the Finnish Foundation of Diabetes Research and the Medical Council of the Academy of Finland (to Dr. Uusitupa).
Source Information
From the Departments of Clinical Neurophysiology (J.P., J.L., E.M.), Clinical Nutrition (L.N., M.U.), and Internal Medicine (L.N., O.S.), University Hospital and University of Kuopio, Kuopio, Finland.
Address reprint requests to Dr. Partanen at the Department of Clinical Neurophysiology, Kuopio University Hospital, P.O. Box 1777, FIN-70211 Kuopio, Finland.
- References
References
1
Pirart J . Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1978;1:168-1882
Lehtinen JM ,Uusitupa M ,Siitonen O ,Pyorala K . Prevalence of neuropathy in newly diagnosed NIDDM and nondiabetic control subjects. Diabetes 1989;38:1307-1313
CrossRef | Web of Science | Medline3
Lehtinen JM ,Niskanen L ,Hyvonen K ,Siitonen O ,Uusitupa M . Nerve function and its determinants in patients with newly-diagnosed type 2 (non-insulin-dependent) diabetes mellitus and in control subjects -- a 5-year follow-up. Diabetologia 1993;36:68-72
CrossRef | Web of Science | Medline4
Uusitupa M ,Siitonen O ,Aro A ,Pyorala K . Prevalence of coronary heart disease, left ventricular failure and hypertension in middle-aged, newly diagnosed type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 1985;28:22-27
CrossRef | Web of Science | Medline5
WHO Expert Committee on Diabetes Mellitus: second report 6
Uusitupa MIJ ,Niskanen LK ,Siitonen O ,Voutilainen E ,Pyorala K . Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 1993;36:1175-1184
CrossRef | Web of Science | Medline7
Niskanen L ,Karjalainen J ,Siitonen O ,Uusitupa M . Metabolic evolution of type 2 diabetes: a 10-year follow-up from the time of diagnosis. J Intern Med 1994;236:263-270
CrossRef | Web of Science | Medline8
Penttila IM ,Voutilainen E ,Laitinen P ,Juutilainen P . Comparison of different analytical and precipitation methods for the direct estimation of serum high-density lipoprotein cholesterol. Scand J Clin Lab Invest 1981;41:353-360
CrossRef | Web of Science | Medline9
Lehtinen J. Diabetic neuropathy in newly diagnosed non-insulin-dependent diabetics. (Ph.D. thesis. Kuopio, Finland: University of Kuopio, 1987.)
10
Lang AH ,Forsstrom J ,Bjorkqvist S-E ,Kuusela V . Statistical variation of nerve conduction velocity: an analysis of normal subjects and uraemic patients. J Neurol Sci 1977;33:229-241
CrossRef | Web of Science | Medline11
Ratzmann KP ,Raschke M ,Gander I ,Schimke E . Prevalence of peripheral and autonomic neuropathy in newly diagnosed type II (non-insulin-dependent) diabetes. J Diabet Complications 1991;5:1-5
CrossRef | Medline12
Mincu I . Micro- and macroangiopathies and other chronic degenerative complications in newly detected diabetes mellitus. Med Interne Romania 1980;18:155-164
Medline13
The Diabetes Control and Complications Trial Research Group
Full Text | Web of Science | Medline14
Harati Y . Frequently asked questions about diabetic peripheral neuropathies. Neurol Clin 1992;10:783-807
Web of Science | Medline15
Cameron NE ,Cotter MA . The relationship of vascular changes to metabolic factors in diabetes mellitus and their role in the development of peripheral nerve complications. Diabetes Metab Rev 1994;10:189-224
CrossRef | Web of Science | Medline16
Scarpini E ,Bianchi R ,Moggio M ,Sciacco M ,Fiori MG ,Scarlato G . Decrease of nerve Na+, K+ -ATPase activity in the pathogenesis of human diabetic neuropathy. J Neurol Sci 1993;120:159-167
CrossRef | Web of Science | Medline17
Dyck PJ ,Karnes JL ,O'Brien P , et al. The spatial distribution of fiber loss in diabetic polyneuropathy suggests ischemia. Ann Neurol 1986;19:440-449
CrossRef | Web of Science | Medline18
Llewelyn JG ,Gilbey SG ,Thomas PK ,King RH ,Muddle JR ,Watkins PJ . Sural nerve morphometry in diabetic autonomic and painful sensory neuropathy: a clinicopathological study. Brain 1991;114:867-892
CrossRef | Web of Science | Medline19
Niskanen LK ,Uusitupa MI ,Sarlund H ,Siitonen O ,Pyorala K . Five-year follow-up study on plasma insulin levels in newly diagnosed NIDDM patients and nondiabetic subjects. Diabetes Care 1990;13:41-48
CrossRef | Web of Science | Medline20
Wahren J ,Johansson B-L ,Wallberg-Henriksson H . Does C-peptide have a physiological role? Diabetologia 1994;37:Suppl 2:S99-S107
CrossRef | Web of Science | Medline
- Citing Articles (121)
Citing Articles
1
Wouter Pluijms, Frank Huygen, Jianguo Cheng, Nagy Mekhail, Maarten van Kleef, Jan Van Zundert, Robert van Dongen. 2011. Painful Diabetic Polyneuropathy. , 145-150.
CrossRef2
Milena De Felice, Raul Sanoja, Ruizhong Wang, Louis Vera-Portocarrero, Janice Oyarzo, Tamara King, Michael H. Ossipov, Todd W. Vanderah, Josephine Lai, Gregory O. Dussor, Howard L. Fields, Theodore J. Price, Frank Porreca. (2011) Engagement of descending inhibition from the rostral ventromedial medulla protects against chronic neuropathic pain. PAIN 152:12, 2701-2709
CrossRef3
Sean Mackey, Ian Carroll, Birol Emir, T. Kevin Murphy, Ed Whalen, Levent Dumenci. (2011) Sensory Pain Qualities in Neuropathic Pain. The Journal of Pain
CrossRef4
Kai McGreevy, Kayode A. Williams. (2011) Contemporary Insights into Painful Diabetic Neuropathy and Treatment with Spinal Cord Stimulation. Current Pain and Headache Reports
CrossRef5
D. K. Shehab, K. F. Al-Jarallah, M. Abraham, O. A. Mojiminiyi, H. Al-Mohamedy, N. A. Abdella. (2011) Back to basics: ankle reflex in the evaluation of peripheral neuropathy in type 2 diabetes mellitus. QJM
CrossRef6
A. Hartemann, N. Attal, D. Bouhassira, I. Dumont, H. Gin, S. Jeanne, G. Said, J.-L. Richard. (2011) Painful diabetic neuropathy: Diagnosis and management. Diabetes & Metabolism 37:5, 377-388
CrossRef7
Yasuyuki Jin, Akira Kanamori, Shogo Ito, Kiyokazu Matoba, Masaaki Miyakawa, Hideaki Kaneshige, Mitsuo Obana, Masahiko Takai, Hiroshi Takeda, Hideo Machimura, Nobuaki Minami, Takahiro Kawata, Shin Honda, Sachio Aoyagi, Hikaru Amemiya, Nobuo Sasai, Michio Nakayama, Yoshikazu Naka, Yasuo Terauchi, Ikuro Matsuba. (2011) Cross-sectional survey of diabetic neuropathy in Kanagawa and clinical significance of a touch test using tissue paper. Journal of Diabetes Investigationno-no
CrossRef8
M. Tavakoli, P. Kallinikos, A. Iqbal, A. Herbert, H. Fadavi, N. Efron, A. J. M. Boulton, R. A Malik. (2011) Corneal confocal microscopy detects improvement in corneal nerve morphology with an improvement in risk factors for diabetic neuropathy. Diabetic Medicine 28:10, 1261-1267
CrossRef9
T Mixcoatl-Zecuatl, CG Jolivalt. (2011) A spinal mechanism of action for duloxetine in a rat model of painful diabetic neuropathy. British Journal of Pharmacology 164:1, 159-169
CrossRef10
L. B. Dahlin, V. Granberg, O. Rolandsson, I. Rosén, E. Dahlin, G. Sundkvist. (2011) Disturbed vibrotactile sense in finger pulps in patients with Type 1 diabetes-correlations with glycaemic level, clinical examination and electrophysiology. Diabetic Medicine 28:9, 1045-1052
CrossRef11
A. Hartemann, N. Attal, D. Bouhassira, I. Dumont, H. Gin, S. Jeanne, G. Said, J.-L. Richard. (2011) Prise en charge de la polyneuropathie diabétique douloureuse. Médecine des Maladies Métaboliques 5:5, H1-H34
CrossRef12
Sahadev A. Shankarappa, Erika S. Piedras-Rentería, Evan B. Stubbs. (2011) Forced-exercise delays neuropathic pain in experimental diabetes: effects on voltage-activated calcium channels. Journal of Neurochemistry 118:2, 224-236
CrossRef13
L. H. Soderstrom, S. P. Johnson, V. A. Diaz, A. G. Mainous III. (2011) Association between vitamin D and diabetic neuropathy in a nationally representative sample: results from 2001-2004 NHANES. Diabetic Medicineno-no
CrossRef14
Nathan Efron. (2011) The Glenn A. Fry Award Lecture 2010: Ophthalmic Markers of Diabetic Neuropathy. Optometry and Vision Science 88:6, 661-683
CrossRef15
Nicholas K. Tentolouris. (2011) Pain: Painful diabetic neuropathy—new choice of first-line therapy?. Nature Reviews Endocrinology 7:7, 381-383
CrossRef16
Wouter Pluijms, Frank Huygen, Jianguo Cheng, Nagy Mekhail, Maarten van Kleef, Jan Van Zundert, Robert van Dongen. (2011) 18. Painful Diabetic Polyneuropathy. Pain Practice 11:2, 191-198
CrossRef17
Howard S. Smith, Charles E. Argoff. (2011) Pharmacological Treatment of Diabetic Neuropathic Pain. Drugs 71:5, 557-589
CrossRef18
Robert W. Hurley, Heidi V. Goldstein, James P. Rathmell. 2011. Painful peripheral neuropathies. , 386-394.
CrossRef19
Sun-Hye Ko, Seung-Hyun Ko. (2011) Letter: Diabetic Polyneuropathy and Cardiovascular Complications in Type 2 Diabetic Patients (Diabetes Metab J 2011;35:390-6). Diabetes & Metabolism Journal 35:5, 558
CrossRef20
Toshihide Kawai, Izumi Takei, Mikiya Tokui, Osamu Funae, Kazunori Miyamoto, Mitsuhisa Tabata, Takumi Hirata, Takao Saruta, Akira Shimada, Hiroshi Itoh. (2010) Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of Nɛ-carboxymethyl lysine. Journal of Diabetes and its Complications 24:6, 424-432
CrossRef21
B. A. Perkins, A. Dholasania, R. A. Buchanan, V. Bril. (2010) Short-term metabolic change is associated with improvement in measures of diabetic neuropathy: a 1-year placebo cohort analysis. Diabetic Medicine 27:11, 1271-1279
CrossRef22
Fadia T. Shaya, Xia Yan, Pei-Jung Lin, Linda Simoni-Wastila, Morgan Bron, Robert Baran, Thomas W. Donner. (2010) US Trends in Glycemic Control, Treatment, and Comorbidity Burden in Patients With Diabetes. The Journal of Clinical Hypertension 12:10, 826-832
CrossRef23
S.-H. Ko, H.-S. Kwon, J.-M. Yu, S.-H. Baik, I.-B. Park, J.-H. Lee, K.-S. Ko, J.-H. Noh, D.-S. Kim, C.-H. Kim, J.-O. Mok, T.-S. Park, H.-S. Son, B.-Y. Cha. (2010) Comparison of the efficacy and safety of tramadol/acetaminophen combination therapy and gabapentin in the treatment of painful diabetic neuropathy. Diabetic Medicine 27:9, 1033-1040
CrossRef24
Juan Ybarra, Josep M. Pou, June Hart Romeo, Javier Merce, Jeroni Jurado. (2010) Transforming growth factor beta 1 as a biomarker of diabetic peripheral neuropathy: cross-sectional study. Journal of Diabetes and its Complications 24:5, 306-312
CrossRef25
Y. Jiang, A.P. Mizisin, A. Rearden, C.G. Jolivalt. (2010) Diabetes induces changes in ILK, PINCH and components of related pathways in the spinal cord of rats. Brain Research 1332, 100-109
CrossRef26
M. Nybo, M. K. Poulsen, J. Grauslund, J. E. Henriksen, L. M. Rasmussen. (2010) Plasma osteoprotegerin concentrations in peripheral sensory neuropathy in Type 1 and Type 2 diabetic patients. Diabetic Medicine 27:3, 289-294
CrossRef27
Christina Daousi, Turo J. Nurmikko. 2010. Painful Diabetic Neuropathy. , 204-221.
CrossRef28
Mohamed Reda Halawa, Abdullah Karawagh, Anwar Zeidan, Alaa-El-Dine H. Mahmoud, Medhat Sakr, Ahmed Hegazy. (2010) Prevalence of painful diabetic peripheral neuropathy among patients suffering from diabetes mellitus in Saudi Arabia. Current Medical Research and Opinion 26:2, 337-343
CrossRef29
S. Thrainsdottir, R. A. Malik, I. Rosén, F. Jakobsson, E. Bakhtadze, J. Petersson, G. Sundkvist, L. B. Dahlin. (2009) Sural nerve biopsy may predict future nerve dysfunction. Acta Neurologica Scandinavica 120:1, 38-46
CrossRef30
Debra P. Ritzwoller, Jennifer L. Ellis, Eli J. Korner, Cynthia L. Hartsfield, Alesia Sadosky. (2009) Comorbidities, healthcare service utilization and costs for patients identified with painful DPN in a managed-care setting. Current Medical Research and Opinion 25:6, 1319-1328
CrossRef31
Solomon Tesfaye. (2009) Advances in the management of diabetic peripheral neuropathy. Current Opinion in Supportive and Palliative Care 3:2, 136-143
CrossRef32
Paul E. Bigeleisen, Nizar Moayeri, Gerbrand J. Groen. (2009) Extraneural versus Intraneural Stimulation Thresholds during Ultrasound-guided Supraclavicular Block. Anesthesiology 110:6, 1235-1243
CrossRef33
Catalina Aranda, Anabel Meza, Raymundo Rodríguez, María Teresa Mantilla, Kathrine Jáuregui-Renaud. (2009) Diabetic Polyneuropathy May Increase the Handicap Related to Vestibular Disease. Archives of Medical Research 40:3, 180-185
CrossRef34
Ann Little, Eva Feldman, Richard AC Hughes, Ann Little. 2009. Enhanced glycemic control for preventing and treating diabetic neuropathy. .
CrossRef35
Vania E. Fernandez, Salahadin Abdi. 2009. PAINFUL DIABETIC PERIPHERAL NEUROPATHY. , 250-255.
CrossRef36
N. O. B. Thomsen, M. Mojaddidi, R. A. Malik, L. B. Dahlin. (2009) Biopsy of the posterior interosseous nerve: a low morbidity method for assessment of peripheral nerve disorders. Diabetic Medicine 26:1, 100-104
CrossRef37
Kenji Karino, Toru Nabika, Masateru Nishiki, Kenji Iijima, Atsushi Nagai, Junichi Masuda. (2009) Evaluation of diabetic neuropathy using the tone-entropy analysis, a noninvasive method to estimate the autonomic nervous function. Biomedical Research 30:1, 1-6
CrossRef38
Cynthia L. Hartsfield, Eli J. Korner, Jennifer L. Ellis, Marsha A. Raebel, John Merenich, Nancy Brandenburg. (2008) Painful Diabetic Peripheral Neuropathy in a Managed Care Setting: Patient Identification, Prevalence Estimates, and Pharmacy Utilization Patterns. Population Health Management 11:6, 317-328
CrossRef39
James L. Edwards, Andrea M. Vincent, Hsinlin T. Cheng, Eva L. Feldman. (2008) Diabetic neuropathy: Mechanisms to management. Pharmacology & Therapeutics 120:1, 1-34
CrossRef40
P. Mantyselka, J. Miettola, L. Niskanen, E. Kumpusalo. (2008) Glucose regulation and chronic pain at multiple sites. Rheumatology 47:8, 1235-1238
CrossRef41
Alexey G. Nikitin, Dariya A. Chudakova, Igor A. Strokov, Tamara R. Bursa, Dimitry A. Chistiakov, Valery.V. Nosikov. (2008) Leu54Phe and Val762Ala polymorphisms in the poly(ADP-ribose)polymerase-1 gene are associated with diabetic polyneuropathy in Russian type 1 diabetic patients. Diabetes Research and Clinical Practice 79:3, 446-452
CrossRef42
Javier Ibáñez, Esteban M. Gorostiaga, Alicia M. Alonso, Luis Forga, Iñaki Argüelles, José L. Larrión, Mikel Izquierdo. (2008) Lower muscle strength gains in older men with type 2 diabetes after resistance training. Journal of Diabetes and its Complications 22:2, 112-118
CrossRef43
Alesia Sadosky, Anne M. McDermott, Nancy A. Brandenburg, Marcie Strauss. (2008) A Review of the Epidemiology of Painful Diabetic Peripheral Neuropathy, Postherpetic Neuralgia, and Less Commonly Studied Neuropathic Pain Conditions. Pain Practice 8:1, 45-56
CrossRef44
Kyung Seok Cheon, Yong Mi An, Cheon Hee Park, Jeong Lyul Kim. (2008) Tourniquet-induced Tibial Nerve Palsy Complicating Partial Lateral Meniscectomy - A case report -. Korean Journal of Anesthesiology 54:1, 81
CrossRef45
Antti J. Metso, Kirsi Palmu, Juhani V. Partanen. (2008) Compound nerve conduction velocity – A reflection of proprioceptive afferents?. Clinical Neurophysiology 119:1, 29-32
CrossRef46
B. Eliot Cole. (2007) Diabetic Peripheral Neuropathic Pain: Recognition and Management. Pain Medicine 8:s2 Duloxetine, S27-S32
CrossRef47
Edward W. Gregg, Qiuping Gu, Desmond Williams, Nathalie de Rekeneire, Yiling J. Cheng, Linda Geiss, Michael Engelgau. (2007) Prevalence of lower extremity diseases associated with normal glucose levels, impaired fasting glucose, and diabetes among U.S. adults aged 40 or older. Diabetes Research and Clinical Practice 77:3, 485-488
CrossRef48
Hitoshi Yasuda, Mitsuru Sanada, Kanako Kitada, Tomoya Terashima, Hyoh Kim, Yoshio Sakaue, Masashi Fujitani, Hiromichi Kawai, Kengo Maeda, Atsunori Kashiwagi. (2007) Rationale and usefulness of newly devised abbreviated diagnostic criteria and staging for diabetic polyneuropathy. Diabetes Research and Clinical Practice 77:3, S178-S183
CrossRef49
Roy Freeman, Philip Raskin, David J. Hewitt, Gary J. Vorsanger, Donna M. Jordan, Jim Xiang, Norman R. Rosenthal. (2007) Randomized study of tramadol/acetaminophen versus placebo in painful diabetic peripheral neuropathy. Current Medical Research and Opinion 23:1, 147-161
CrossRef50
(2007) Traitement médicamenteux du diabète de type 2recommandation de bonne pratique. Diabetes & Metabolism 33:1, S26-S105
CrossRef51
Ryuichi Iwakiri, Kazuma Fujimoto. (2006) Diabetic gastropathy and interstitial cells of Cajal: a clue for bringing understanding out of chaos?. Journal of Gastroenterology 41:11, 1128-1130
CrossRef52
M. Janghorbani, H. Rezvanian, A. Kachooei, A. Ghorbani, A. Chitsaz, F. Izadi, M. Amini. (2006) Peripheral neuropathy in type 2 diabetes mellitus in Isfahan, Iran: prevalence and risk factors. Acta Neurologica Scandinavica 114:6, 384-391
CrossRef53
AI Vinik. (2006) Neuropathies in children and adolescents with diabetes: the tip of the iceberg. Pediatric Diabetes 7:6, 301-304
CrossRef54
A. GIRACH, D. MANNER, M. PORTA. (2006) Diabetic microvascular complications: can patients at risk be identified? A review. International Journal of Clinical Practice 60:11, 1471-1483
CrossRef55
Fei Li, Omorodola I. Abatan, Howard Kim, Diana Burnett, Dennis Larkin, Irina G. Obrosova, Martin J. Stevens. (2006) Taurine reverses neurological and neurovascular deficits in Zucker diabetic fatty rats. Neurobiology of Disease 22:3, 669-676
CrossRef56
Aaron Vinik, Jagdeesh Ullal, Henri K Parson, Carolina M Casellini. (2006) Diabetic neuropathies: clinical manifestations and current treatment options. Nature Clinical Practice Endocrinology & Metabolism 2:5, 269-281
CrossRef57
A. F. J. E. Vrancken, S. Kalmijn, F. Brugman, G. J. E. Rinkel, N. C. Notermans. (2006) The meaning of distal sensory loss and absent ankle reflexes in relation to age. Journal of Neurology 253:5, 578-589
CrossRef58
Charles E. Argoff, B. Eliot Cole, David A. Fishbain, Gordon A. Irving. (2006) Diabetic Peripheral Neuropathic Pain: Clinical and Quality-of-Life Issues. Mayo Clinic Proceedings 81:4, S3-S11
CrossRef59
Rod S. Taylor. (2006) Epidemiology of Refractory Neuropathic Pain. Pain Practice 6:1, 22-26
CrossRef60
Betul M. Gundogdu. (2006) Diabetic peripheral neuropathy: An update on pathogenesis and management. Current Neurology and Neuroscience Reports 6:1, 1-4
CrossRef61
Eugenia Rota, Roberto Quadri, Edoardo Fanti, Gianluca Isoardo, Fabio Poglio, Alessia Tavella, Ilaria Paolasso, Palma Ciaramitaro, Bruno Bergamasco, Dario Cocito. (2005) Electrophysiological findings of peripheral neuropathy in newly diagnosed type II diabetes mellitus. Journal of the Peripheral Nervous System 10:4, 348-353
CrossRef62
Roy Freeman. (2005) Newer agents for the treatment of painful diabetic peripheral neuropathy. Current Diabetes Reports 5:6, 409-416
CrossRef63
Moaz Mojaddidi, Cristian Quattrini, Mitra Tavakoli, Rayaz A. Malik. (2005) Recent developments in the assessment of efficacy in clinical trials of diabetic neuropathy. Current Diabetes Reports 5:6, 417-422
CrossRef64
Mugdha Gore, Nancy A. Brandenburg, Ellen Dukes, Deborah L. Hoffman, Kei-Sing Tai, Brett Stacey. (2005) Pain Severity in Diabetic Peripheral Neuropathy is Associated with Patient Functioning, Symptom Levels of Anxiety and Depression, and Sleep. Journal of Pain and Symptom Management 30:4, 374-385
CrossRef65
Peter D. Donofrio, Philip Raskin, Norman R. Rosenthal, David J. Hewitt, Donna M. Jordan, Jim Xiang, Aaron I. Vinik. (2005) Safety and effectiveness of topiramate for the management of painful diabetic peripheral neuropathy in an open-label extension study. Clinical Therapeutics 27:9, 1420-1431
CrossRef66
H. H. Kr
mer, R. Rolke, M. Hecht, A. Bickel, F. Birklein. (2005) Follow-up of advanced diabetic neuropathy. Journal of Neurology 252:3, 315-320
CrossRef67
R Norman Harden. (2005) Chronic Neuropathic Pain. The Neurologist 11:2, 111-122
CrossRef68
A. Gottsater, M. Kangro, G. Sundkvist. (2004) Early parasympathetic neuropathy associated with elevated fasting plasma C-peptide concentrations and late parasympathetic neuropathy with hyperglycaemia and other microvascular complications. Diabetic Medicine 21:12, 1304-1309
CrossRef69
Clifton Gooch, David Podwall. (2004) The Diabetic Neuropathies. The Neurologist 10:6, 311-322
CrossRef70
C. Daousi, I. A. MacFarlane, A. Woodward, T. J. Nurmikko, P. E. Bundred, S. J. Benbow. (2004) Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabetic Medicine 21:9, 976-982
CrossRef71
Andrew J Palmer, William J Valentine, Joshua A Ray. (2004) Cost-effectiveness studies of diabetes prevention in high-risk patients. Expert Review of Pharmacoeconomics & Outcomes Research 4:4, 393-402
CrossRef72
Haig Tcheurekdjian, Tonya Palermo, Robert Hostoffer. (2004) Quality of life in common variable immunodeficiency requiring intravenous immunoglobulin therapy. Annals of Allergy, Asthma & Immunology 93:2, 160-165
CrossRef73
Michael C Rowbotham, Veeraindar Goli, Nadia R Kunz, Dean Lei. (2004) Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 110:3, 697-706
CrossRef74
Vincent Minville, Paul Joseph Zetlaoui, Christine Fessenmeyer, Dan Benhamou. (2004) Ultrasound Guidance ror Difficult Lateral Popliteal Catheter Insertion in a Patient With Peripheral Vascular Disease. Regional Anesthesia and Pain Medicine 29:4, 368-370
CrossRef75
A.I Vinik, Anahit Mehrabyan. (2004) Diabetic neuropathies. Medical Clinics of North America 88:4, 947-999
CrossRef76
M Manfredi, MJ McCullough, P Vescovi, ZM Al-Kaarawi, SR Porter. (2004) Update on diabetes mellitus and related oral diseases. Oral Diseases 10:4, 187-200
CrossRef77
Sarah M. Sweitzer, Satyanarayana Medicherla, Ramona Almirez, Sundeep Dugar, Sarvajit Chakravarty, Jennifer A. Shumilla, David C. Yeomans, Andrew A. Protter. (2004) Antinociceptive action of a p38α MAPK inhibitor, SD-282, in a diabetic neuropathy model. Pain 109:3, 409-419
CrossRef78
P. Marchettini, L. Teloni, F. Formaglio, M. Lacerenza. (2004) Pain in diabetic neuropathy case study: whole patient management. European Journal of Neurology 11:s1, 12-21
CrossRef79
S.I. Ismailov, D.M. Berdykulova, F.A. Khaidarova. (2004) Late Complications of Diabetes mellitus in the Republic of Uzbekistan. Heart Drug 4:4, 177-183
CrossRef80
Andrew J Palmera, Stéphane Rozea, William J Valentinea, Michael E Minshallb, Volker Foosa, Francesco M Luratia, Morten Lammerta, Giatgen A Spinasc. (2004) Validation of the CORE Diabetes Model Against Epidemiological and Clinical Studies. Current Medical Research and Opinion 20:s1, S27-S40
CrossRef81
David Podwall, Clifton Gooch. (2004) Diabetic neuropathy: Clinical features, etiology, and therapy. Current Neurology and Neuroscience Reports 4:1, 55-61
CrossRef82
Andrew J. Palmer, Stéphane Roze, William J. Valentine, Michael E. Minshallb, Clarice Hayes, Alan Oglesby, Giatgen A. Spinas. (2004) Impact of Changes in HbA1c, Lipids and Blood Pressure on Long-term Outcomes in Type 2 Diabetes Patients: An Analysis Using the CORE Diabetes Model. Current Medical Research and Opinion 20:s1, S53-S58
CrossRef83
Andrew J. Palmer, Stéphane Roze, William J. Valentine, Michael E. Minshall, Volker Foos, Francesco M. Lurati, Morten Lammert, Giatgen A. Spinas. (2004) The CORE Diabetes Model: Projecting Long-term Clinical Outcomes, Costs and Costeffectiveness of Interventions in Diabetes Mellitus (Types 1 and 2) to Support Clinical and Reimbursement Decision-making. Current Medical Research and Opinion 20:s1, S5-S26
CrossRef84
D.K. Kochar. (2004) Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study. QJM 97:1, 33-38
CrossRef85
Leo Niskanen, Jukka Luoma, Maarku Laakso. (2003) Reply. Metabolism 52:12, 1648-1649
CrossRef86
Brian D. Sites, John Gallagher, Michael Sparks. (2003) Ultrasound-Guided Popliteal Block Demonstrates an Atypical Motor Response to Nerve Stimulation in 2 Patients With Diabetes Mellitus. Regional Anesthesia and Pain Medicine 28:5, 479-482
CrossRef87
Gun E Sandberg, Karin F Wikblad. (2003) Oral dryness and peripheral neuropathy in subjects with type 2 diabetes. Journal of Diabetes and its Complications 17:4, 192-198
CrossRef88
Michael I Weintraub, Gil I Wolfe, Richard A Barohn, Steven P Cole, Gareth J Parry, Ghazala Hayat, Jeffrey A Cohen, Jeffrey C Page, Mark B Bromberg, Sherwyn L Schwartz. (2003) Static magnetic field therapy for symptomatic diabetic neuropathy: a randomized, double-blind, placebo-controlled trial. Archives of Physical Medicine and Rehabilitation 84:5, 736-746
CrossRef89
Hitoshi Yasuda, Masahiko Terada, Kengo Maeda, Shuro Kogawa, Mitsuru Sanada, Masakazu Haneda, Atsunori Kashiwagi, Ryuichi Kikkawa. (2003) Diabetic neuropathy and nerve regeneration. Progress in Neurobiology 69:4, 229-285
CrossRef90
R. J. Tapp, J. E. Shaw, M. P. de Courten, D. W. Dunstan, T. A. Welborn, P. Z. Zimmet. (2003) Foot complications in Type 2 diabetes: an Australian population-based study. Diabetic Medicine 20:2, 105-113
CrossRef91
M WEI, L ONG, M SMITH, F ROSS, K SCHMID, A HOEY, D BURSTOW, L BROWN. (2003) The streptozotocin-diabetic rat as a model of the chronic complications of human diabetes. Heart, Lung and Circulation 12:1, 44-50
CrossRef92
D. K. Kochar, N. Jain, R. P. Agarwal, T. Srivastava, P. Agarwal, S. Gupta. (2002) Sodium valproate in the management of painful neuropathy in type 2 diabetes - a randomized placebo controlled study. Acta Neurologica Scandinavica 106:5, 248-252
CrossRef93
Kenneth E. Schmader. (2002) Epidemiology and Impact on Quality of Life of Postherpetic Neuralgia and Painful Diabetic Neuropathy. The Clinical Journal of Pain 18:6, 350-354
CrossRef94
Zachary Simmons, Eva L. Feldman. (2002) Update on diabetic neuropathy. Current Opinion in Neurology 15:5, 595-603
CrossRef95
Vitomir Rankovic, D. Micic, Vladimir Bumbasirevic, I. Palibrk, Marica Basic, V. Bukumirovic. (2002) Anestezija kod bolesnika sa diabetes mellitusom. Acta chirurgica iugoslavica 49:1, 47-55
CrossRef96
Amanda Adler. (2001) Risk factors for diabetic neuropathy and foot ulceration. Current Diabetes Reports 1:3, 202-207
CrossRef97
James R. Tonra, Kenneth D. Cliffer, Susan R. Carson, Ronald M. Lindsay, Sue C. Bodine, Peter S. DiStefano. (2001) Reduced Ia-Afferent-Mediated Hoffman Reflex in Streptozotocin-Induced Diabetic Rats. Experimental Neurology 172:1, 220-227
CrossRef98
Tuomilehto, Jaakko, Lindström, Jaana, Eriksson, Johan G., Valle, Timo T., Hämäläinen, Helena, Ilanne-Parikka, Pirjo, Keinänen-Kiukaanniemi, Sirkka, Laakso, Mauri, Louheranta, Anne, Rastas, Merja, Salminen, Virpi, Aunola, Sirkka, Cepaitis, Zygimantas, Moltchanov, Vladislav, Hakumäki, Martti, Mannelin, Marjo, Martikkala, Vesa, Sundvall, Jouko, Uusitupa, Matti, . (2001) Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance. New England Journal of Medicine 344:18, 1343-1350
Full Text99
P. A. Scherpereel, B. Tavernier. (2001) Perioperative care of diabetic patients. European Journal of Anaesthesiology 18:5, 277-294
CrossRef100
(2001) Clinical scenario. Diabetic Medicine 18:5, 7-11
CrossRef101
A. Ambrosch, J. Dierkes, R. Lobmann, W. Kühne, W. König, C. Luley, H. Lehnert. (2001) Relation between homocysteinaemia and diabetic neuropathy in patients with Type 2 diabetes mellitus. Diabetic Medicine 18:3, 185-192
CrossRef102
N Tentolouris. (2001) Peripheral neuropathy does not invariably coexist with autonomic neuropathy in diabetes mellitus. European Journal of Internal Medicine 12:1, 20-27
CrossRef103
M. Baba, I. Ozaki. (2001) Electrophysiological Changes in Diabetic Neuropathy: From Subclinical Alterations to Disabling Abnormalities. Archives Of Physiology And Biochemistry 109:3, 234-240
CrossRef104
T. -C. Hsu, C. -L. Wang, Y. -W. Shau, F. -T. Tang, K. -L. Li, C. -Y. Chen. (2000) Altered heel-pad mechanical properties in patients with Type 2 diabetes mellitus. Diabetic Medicine 17:12, 854-859
CrossRef105
Kazuhiro Sugimoto, Yuichi Murakawa, Weixian Zhang, Gang Xu, Anders A. F. Sima. (2000) Insulin receptor in rat peripheral nerve: its localization and alternatively spliced isoforms. Diabetes/Metabolism Research and Reviews 16:5, 354-363
CrossRef106
Ryuichi Wada, Motoi Koyama, Hiroki Mizukami, Hiroyuki Odaka, Hitoshi Ikeda, Soroku Yagihashi. (1999) Effects of long-term treatment with α-glucosidase inhibitor on the peripheral nerve function and structure in Goto-Kakizaki rats: a genetic model for Type 2 diabetes. Diabetes/Metabolism Research and Reviews 15:5, 332-337
CrossRef107
S. J. Benbow, L. Cossins, I. A. MacFarlane. (1999) Painful diabetic neuropathy. Diabetic Medicine 16:8, 632-644
CrossRef108
S.J. Benbow, I.A. MacFarlane. (1999) Painful diabetic neuropathy. Best Practice & Research Clinical Endocrinology & Metabolism 13:2, 295-308
CrossRef109
Sanjeev Kumar Bhardwaj, Sukhjit Kaur Sandhu, Poonam Sharma, Gurcharan Kaur. (1999) Impact of diabetes on CNS: Role of signal transduction cascade. Brain Research Bulletin 49:3, 155-162
CrossRef110
Carolyn N de Wytt, Richard V Jackson, Gregory I Hockings, Julie M Joyner, Christopher R Strakosch. (1999) Polyneuropathy in Australian Outpatients with Type II Diabetes Mellitus. Journal of Diabetes and its Complications 13:2, 74-78
CrossRef111
A. Gottsater, M. Ahmed, P. Fernlund, G. Sundkvist. (1999) Autonomic neuropathy in Type 2 diabetic patients is associated with hyperinsulinaemia and hypertriglyceridaemia. Diabetic Medicine 16:1, 49-54
CrossRef112
Rayaz A Malik, Sheila Williamson, Caroline Abbott, Anne L Carrington, Jawaid Iqbal, Wolfgang Schady, Andrew JM Boulton. (1998) Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. The Lancet 352:9145, 1978-1981
CrossRef113
J. Tovi, E. Svanborg, B.-Y. Nilsson, P. Engfeldt. (1998) Diabetic neuropathy in elderly Type 2 diabetic patients: effects of insulin treatment. Acta Neurologica Scandinavica 98:5, 346-353
CrossRef114
Jonathan E Shaw, Allison M Hodge, Maximilian de Courten, Gary K Dowse, Hassam Gareeboo, Jaakko Tuomilehto, K.George M.M Alberti, Paul Z Zimmet. (1998) Diabetic neuropathy in Mauritius: prevalence and risk factors. Diabetes Research and Clinical Practice 42:2, 131-139
CrossRef115
Andrew J.M. Boulton, Rayaz A. Malik. (1998) DIABETIC NEUROPATHY. Medical Clinics of North America 82:4, 909-929
CrossRef116
John F. Connolly, Thomas A. Csencsitz. (1998) Limb Threatening Neuropathic Complications From Ankle Fractures in Patients With Diabetes. Clinical Orthopaedics and Related Research 348, 212???219
CrossRef117
Jeffrey A. Cohen, Barrett W. Jeffers, Dianne Faldut, Mark Marcoux, Robert W. Schrier. (1998) Risks for sensorimotor peripheral neuropathy and autonomic neuropathy in non-insulin-dependent diabetes mellitus (NIDDM). Muscle & Nerve 21:1, 72-80
CrossRef118
G. Sundkvist, B. Lilja, H. Nilsson, J.-
CrossRef119
Vincenza Spallone, M.Rosaria Maiello, Elena Cicconetti, Guido Menzinger. (1997) Autonomic neuropathy and cardiovascular risk factors in insulin-dependent and non insulin-dependent diabetes. Diabetes Research and Clinical Practice 34:3, 169-179
CrossRef120
Matti I. J. Uusitupa. (1996) Early Lifestyle Intervention in Patients with Non-insulin-dependent Diabetes Mellitus and Impaire Glucose Tolerance. Annals of Medicine 28:5, 445-449
CrossRef121
H. Viinamäki, L. Niskanen, M. Uusitupa. (1995) Mental well-being in people with non-insulin-dependent diabetes. Acta Psychiatrica Scandinavica 92:5, 392-397
CrossRef
